Source: Annual Congress 2004 - Pulmonary embolism
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
I. K. Oguzulgen, N. Ekim, B. Donmez, N. Akar (Ankara, Turkey). The relation between the tissue-plasminogen activator gene polymorphism and venous thromboembolism. Eur Respir J 2004; 24: Suppl. 48, 4194

Member's Comments

No comment yet.

Related content which might interest you: The relation between plasminogen activator inhibitor-1 (PAI-1) and inflammatory markers in COPD: A possible risk factor of inflammation-induced thrombosis Source: International Congress 2017 – Systemic and airway biomarkers Year: 2017 Genetic polymorphisms associated with acute pulmonary embolism and deep venous thrombosis Source: Eur Respir J 2003; 21: 25-30 Year: 2003 Pro-urokinase up-regulates the expression of urokinase type plasminogen activator (u-PA) in human pulmonary arterial endothelial cells Source: Eur Respir J 2007; 30: Suppl. 51, 143s Year: 2007 Urokinase plasminogen activator receptor polymorphisms and airway remodelling in asthma Source: Eur Respir J 2016; 47:1568-1571 Year: 2016 Half - dose of recombinant tissue-type plasminogen activator in the treatment of acute pulmonary embolism: long term outcomes Source: International Congress 2017 – Prognostic factors and outcomes in pulmonary embolism Year: 2017 Enoxaparin reduced ventilation-induced plasminogen activator inhibitor-1 Source: Annual Congress 2009 - Crossing the line: alveolo-capillary barrier control in acute lung injury Year: 2009 Efficacy of thrombolytic agents in the treatment of pulmonary embolism Source: Eur Respir J 2005; 26: 864-874 Year: 2005 The role of angiotensin converting enzyme gene polymorphism in pulmonary thromboembolism Source: Annual Congress 2004 - Pulmonary embolism Year: 2004 Efficiency of r-TPA therapy in major venous thromboembolism Source: Eur Respir J 2007; 30: Suppl. 51, 83s Year: 2007 Suppression of plasminogen activator inhibitor-1 by RNA interference attenuates pulmonary fibrosis Source: Annual Congress 2010 - Experimental approaches in pulmonary fibrosis Year: 2010 PLA2 polymorphism of platelet glycoprotein IIb/IIIa but not Factor V Leiden and prothrombin G20210A polymorphisms is associated with venous thromboembolism and more recurrent events Source: Annual Congress 2012 - Pulmonary circulation: clinical diagnosis, treatment, end-points and animal models Year: 2012 The G20210A polymorphism of the prothrombin gene is the strong genetic risk factor for the pulmonary embolism development in young patients Source: Eur Respir J 2004; 24: Suppl. 48, 556s Year: 2004 Genetic and acquired risk factors of venous thromboembolism Source: ISSN=1025-448x, ISBN=1-904097-31-6, page=1 Year: 2004 The regulation of plasminogen activator inhibitor-1 (PAI-1) production with dexamethasone by human lung fibroblasts Source: Eur Respir J 2005; 26: Suppl. 49, 343s Year: 2005 Fibrinogen Aα Thr312Ala polymorphism is associated with chronic thromboembolic pulmonary hypertension Source: Eur Respir J 2008; 31: 736-741 Year: 2008 Upregulation of the gene encoding the urokinase-type plasminogen activator (uPA) in respiratory muscles of COPD patients Source: Annual Congress 2004 - Skeletal muscle in respiratory disease Year: 2004 Soluble urokinase plasminogen activator receptor (suPAR) is associated with COPD readmission and mortality Source: International Congress 2019 – Long-term lung function: from early birth to adulthood Year: 2019 Venous thromboembolism and arterial atherosclerosis: a bidirectional association Source: Virtual Congress 2020 – Cardiovascular morbidity and mortality after pulmonary embolism Year: 2020 Soluble urokinase plasminogen activator receptor (suPAR) predicts mortality in exacerbated COPD Source: International Congress 2018 – New predictors of morbidity and mortality in COPD Year: 2018 The relevant research of pulmonary thromboembolism and Protein C gene polymorphism Source: Annual Congress 2010 - Pulmonary venous thromboembolic disease Year: 2010